Refractory epilepsy in adults;Epilepsia refractaria del adulto

Revista de Neurologia

Volumn 35, Issue 10, 2002, Pages 931-953

  Sánchez Álvarez, Juan Carlos ^a   Serrano Castro, P J ^b   Canadillas Hidalgo F ^c  

^a HOSPITAL UNIVERSITARIO VIRGEN DE LAS NIEVES   (Spain)

^b Hospital de Torrecardenas   (Spain)

^c HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

Author keywords

Antiepileptic drugs; Drug resistant epilepsy; Epilepsy surgery; Refractory epilepsy; Temporal lobe epilepsy; Untreatable epilepsy

Indexed keywords

ANTICONVULSIVE AGENT; BENZODIAZEPINE DERIVATIVE; CARBAMAZEPINE; GABAPENTIN; LAMOTRIGINE; PHENOBARBITAL; PHENYTOIN; TIAGABINE; TOPIRAMATE; VALPROIC ACID; VIGABATRIN;

ADULT; BRAIN SURGERY; DAILY LIFE ACTIVITY; DOSE RESPONSE; EPILEPSY; HUMAN; PROGNOSIS; QUALITY OF LIFE; RECURRENT DISEASE; REVIEW; SEIZURE; TEMPORAL LOBE EPILEPSY;

EID: 0037121409     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: 10.33588/rn.3510.2002142     Document Type: Review

References (299)

1. Macdonald RL, Meldrum BS. General principles. Principles of antiepileptic drug action. In Levy RH, Mattson RH, Meldrum BS, eds. Antiepileptic Drugs. 4 Ed. New York: Raven Press; 1995. p. 61-77.
2. Shorvon S, ed. Handbook of Epilepsy Treatment. Oxford: Blackwell Science; 2000.
3. French JA. Antiepileptic drug development. In Wyllie E, ed. The Treatment of Epilepsies. 3 Ed. Philadelphia: Lippincott Williams & Wilkins; 2001. p. 719-27.
4. Collaborative Group for the Study of Epilepsy. Prognosis of epilepsy in newly referred patients. A multicenter prospective study of the effects of monotherapy on the long-term course of epilepsy. Epilepsia 1992; 33: 45-51.
5. Cockerell OC, Johnson AL, Sander JWAS, Shorvon SD. Prognosis of epilepsy: A review and further analysis of the first 9 years of the British National General Practice Study of Epilepsy, a prospective population-based study. Epilepsia 1997; 38: 31-46.
6. Dichter MA. Mechanisms of action of new antiepileptic drugs. Adv Neurol 1998; 76: 1-9.
7. Brodie MJ, Dichter MA. Antiepileptic drugs. N Engl J Med 1996; 334: 168-75.
8. Dichter MA, Brodie MJ. New antiepileptic drugs. N Engl J Med 1996; 334: 1583-90.
9. Marson AG, Chadwick DW. New drugs treatments for epilepsy. J Neurol Neurosurg Psychiatry 2001; 70: 143-7.
10. Devinsky O, Cramer J. Safety and efficacy of standard and new antiepileptic drugs. Neurology 2000; 55 (Suppl 3): S5-10.
11. Serrano-Castro PJ, Sánchez-Alvarez JC. Controversias en torno a los nuevos fármacos antiepilépticos. Rev Neurol 2001; 31: 165-71.
12. Engel J Jr. Surgery for seizures. N Engl J Med 1996; 334: 647-52.
13. Wieser HG. Epilepsy surgery: Past, present and future. Seizure 1998; 7: 173-84.
14. Sánchez-Alvarez JC, Altuzarra-Corral A. Cirugía de la epilepsia. Rev Neurol 2001; 33: 353-68.
15. Baker GA, Hesdon B, Marson AG. Quality-of-life and behavioral outcome measures in randomized controlled trials of antiepileptic drugs: A systematic review of methodology and reporting standards. Epilepsia 2000; 41: 1357-63.
16. Heaney D. The pharmacoeconomics of the new antiepileptic drugs. Epilepsia 1999; 40 (Suppl 8): S25-31.
17. Wheelock I, Peterson C, Buchtel HA. Presurgical expectations, postsurgery satisfaction, and psychosocial adjustment after epilepsy surgery. Epilepsia 1998; 39: 487-94.
18. Silfvenius H. Cost and cost-effectiveness of epilepsy surgery. Epilepsia 1999; 40 (Suppl 8): S32-9.
19. Juul-Jensen P. Epidemiology of intractable epilepsy. In Schmidt D, Morselli P, eds. Intractable epilepsy. New York: Raven Press; 1986. p. 5-11.
20. Bourgeois BFD. General concepts of medical intractability. In Lüders H, ed. Epilepsy surgery. New York: Raven Press; 1991. p. 77-81.
21. Schmidt D. Medical intractability in partial epilepsies. In Lüders H, ed. Epilepsy Surgery. New York: Raven Press; 1991. p. 83-90.
22. Aicardi J, Shorvon SD. Intractable epilepsy. In Engel J Jr, Pedley TA, eds. Epilepsy: A Comprehensive Textbook. Philadelphia: Lippincott-Raven; 1997. p. 1325-31.
23. Devinsky O. Patients with refractory seizures. N Engl J Med 1999; 340: 1565-70.
24. Arroyo S. Evaluación de la epilepsia farmacorresistente. Rev Neurol 2000; 30: 881-6.
25. Benbadis SR, Tatum WO, Vale FL. When drugs don't work. An algorithmic approach to medically intractable epilepsy. Neurology 2000; 55: 1780-4.
26. Benbadis SR, Hauser WA. An estimate of the prevalence of psychogenic nonepileptic seizures. Seizure 2000; 9: 280-1.
27. Schmidt D. Syncopes and seizures. Curr Opin Neurol 1996; 9: 78-81.
28. Berg AT, Shinnar S, Levy SR, Testa FM, Smith-Rapaport S, Beckerman B. Early development of intractable epilepsy in children: A prospective study. Neurology 2001; 56: 1445-52.
29. Schmidt D. Two antiepileptic drugs for intractable epilepsy with complex partial seizures. J Neurol Neurosurg Psychiatry 1982; 45: 1119-24.
30. Hermanns G, Noachtar S, Tuxhorn I, Holthausen H, Ebner A, Wolf P. Systematic testing of medical intractability for carbamazepine, phenytoin, and phenobarbital or primidone in monotherapy for patients considered for epilepsy surgery. Epilepsia 1996; 37: 675-9.
31. Kwan P, Brodie MJ. Early identification of refractory epilepsy. N Engl J Med 2000; 342: 314-9.
32. Schmidt D, Gram L. Monotherapy versus polytherapy in epilepsy: A reappraisal. CNS Drugs 1995; 3: 194-208.
33. Oxbury JM. Drug treatment: Adults. In Oxbury J, Polkey C, Duchowny M, eds. Intractable Focal Epilepsy. London: Harcourt Publishers; 2000. p. 475-90.
34. Gilman JT. Drug treatment: Children. In Oxbury J, Polkey C, Duchowny M, eds. Intractable Focal Epilepsy. London: Harcourt Publishers; 2000. p. 491-504.
35. Elices E, Arroyo S. Epilepsias parciales farmacorresistentes. Estrategias terapéuticas en el adulto. Rev Neurol 2001; 33: 76-81.
36. Hauser WA. Incidence and prevalence. In Engel J Jr, Pedley TA, eds. Epilepsy: A Comprehensive Textbook. Philadelphia: Lippincott-Raven Publishers; 1997. p. 47-57.
37. Zarrelli MM, Beghi E, Rocca WA, Hauser WA. Incidence of epileptic syndromes in Rochester, Minnesota: 1980-1984. Epilepsia 1999; 40: 1708-14.
38. Shorvon SD. The epidemiology and treatment of chronic and refractory epilepsy. Epilepsia 1996; 37 (Suppl 2): S1-3.
39. Crawford PM. Epidemiology of intractable focal epilepsy. In Oxbury J, Polkey C, Duchowny M, eds. Intractable Focal Epilepsy. London: Harcourt Publishers; 2000. p. 25-40.
40. Sillampää M, Jalava M, Kaleva O, Shinnar S. Long-term prognosis of seizures with onset in childhood. N Engl J Med 1998; 338: 1715-22.
41. Hauser WA. The natural history of drug resistant epilepsy: Epidemiologic considerations. In Theodore WH, ed. Surgical Treatment of Epilepsy. Amsterdam: Elsevier; 1992. p. 25-8.
42. Berg AT, Levy SR, Novotny EJ, Shinnar S. Predictors of intractable epilepsy in childhood: A case-control study. Epilepsia 1996; 37: 24-30.
43. Ko TS, Holmes GL. EEG and clinical predictors of medically intractable childhood epilepsy. Clin Neurophysiol 1999; 110: 1245-51.
44. Sillampää M. Remission of seizures and predictors of intractability in long-term follow-up. Epilepsia 1993; 34: 930-6.
45. Camfield C, Camfield P, Gordon K, Dooley J. Does the number of seizures before treatment influence ease of control or remission of childhood epilepsy? Not if the number is 10 or less. Neurology 1996; 46: 41-4.
46. MacDonald BK, Johnson AL, Goodridge DM, Cockerell OC, Sander JW, Shorvon SD. Factors predicting prognosis of epilepsy after presentation with seizures. Ann Neurol 2000; 48: 833-41.
47. Elwes RDC, Johnson AL, Shorvon SD, Reynolds EH. The prognosis for seizures control in newly diagnosed epilepsy. N Engl J Med 1984; 311: 944-7.
48. Mattson RH, Cramer JA, Collins JF, and the Department of Veterans Affairs Epilepsy Cooperative Studies No. 118 and No. 264 Group. Prognosis for total control of complex partial and secondarily generalized tonic clonic seizures. Neurology 1996; 47: 68-76.
49. Loiseau P, Jallon P. Epilepsies pharmacorésistantes de l'adulte. Rev Neurol (Paris) 1995; 151: 295-306.
50. Semah F, Picot MC, Adam C, Broglin D, Arzimanoglou A, Bazin B, et al. Is the underlying cause of epilepsy a major prognostic factor for recurrence? Neurology 1998; 51: 1256-62.
51. Stephen LJ, Kwan P, Brodie MJ. Does the cause of localisation-related epilepsy influence the response to antiepileptic drug treatment? Epilepsia 2001; 42: 357-62.
52. Hart YM, Sander JW, Johnson AL, Shorvon SD. National General Practice Study of Epilepsy: Recurrence after a first seizure. Lancet 1990; 336: 1271-4.
53. Kim WJ, Park SCh, Lee SJ, Kim JY, Lee BI, Kim DI. The prognosis for control of seizures with medications in patients with MRI evidence for mesial temporal sclerosis, Epilepsia 1999; 40: 290-3.
54. Raymond AA, Fish DR, Sisodiya SM, Alsanjari N, Stevens JM, Shorvon SD. Abnormalities of gyration, heterotopias, tuberous sclerosis, focal cortical dysplasia, microdysgenesis, dysembryoplastic neuroepithelial tumour and dysgenesis of the archicortex in epilepsy. Clinical, EEG and neuroimaging features in 100 adult patients. Brain 1995; 118: 629-60.
55. Andermann F, Palmini AL. Neuronal migration disorder, tuberous sclerosis and Sturge-Weber syndrome. In Lüders H, ed. Epilepsy Surgery. New York: Raven Press; 1991. p. 203-12.
56. Rodin E, Klutke G, Chayasirisobohn S, Epileptic patients who are refractory to anticonvulsant medications. Neurology 1982; 32: 1382-4.
57. Regesta G, Tanganelli P. Clinical aspects and biological bases of drug-resistant epilepsies. Epilepsy Res 1999; 34: 109-22.
58. Medical Research Council Antiepileptic Drug Withdrawal Study Group. Randomised study of antiepileptic drug withdrawal in patients in remission. Lancet 1991; 337: 1175-80.
59. Wada K, Kiryu K, Kawata Y, Chiba T, Mizuno K, Okada M, et al. Prognosis and clinical features of intractable epilepsy: A prospective study. Psychiatry Clin Neurosci 1997; 51: 233-5.
60. Trinka E, Martin F, Luef G, Unterberger I, Bauer G. Chronic epilepsy with complex partial seizures is not always medically intractable: A long-term observational study. Acta Neurol Stand 2001; 103: 219-25.
61. Feksi AT, Kaamugisha J, Sander JW, Gatiti S, Shorvon SD. Comprehensive primary health care antiepileptic drug treatment programme in rural and semi-urban Kenya. ICBERG (International Community-based Epilepsy Research Group). Lancet 1991; 337: 406-9.
62. Musicco M, Beghi E, Solari A, Viani F. Treatment of first tonic-clonic seizure does not improve the prognosis of epilepsy. First Seizure Trial Group (FIRST Group). Neurology 1997; 49: 991-8.
63. Berg AT, Shinnar S. Do seizures beget seizures? An assessment of the clinical evidence in humans. J Clin Neurophysiol 1997; 14: 102-10.
64. Jallon P. The problem of intractability: The continuing need for new medical therapies in epilepsy. Epilepsia 1997; 38 (Suppl 9): S37-42.
65. Tishler DM, Weinberg KI, Hinton DR, Barbaro N, Annett GM, Raffel C. MDR1 gene expression in brain of patients with medically intractable epilepsy. Epilepsia. 1995; 36: 1-6.
66. Ramsay RE, Cohen A, Brown MC. Coexisting epilepsy and non-epileptic seizures. In Rowan AJ, Gates JR, eds. Non-epileptic Seizures. Boston: Butter-worth-Heinemann; 1993. p. 47-54.
67. Lesser RP. Psychogenic seizures. Neurology 1996; 46: 1499-507.
68. Krumholz A. Nonepileptic seizures: Diagnosis and management. Neurology 1999; 53 (Suppl 2): S76-83.
69. Walczak TS, Papacostas S, Williams DT, Scheuer ML, Lebowitz N, Notarfrancesco A. Outcome after diagnosis of psychogenic nonepileptic seizures. Epilepsia 1995; 36: 1131-7.
70. Somers VK, Abboud FM. Neurocardiogenic syncope. Adv Intern Med 1996; 41: 399-435.
71. Zaidi A, Crampton S, Clough P, Fitzpatrick A, Scheepers B. Head-up tilting is a useful provocative test for psychogenic non-epileptic seizures. Seizure 1999; 8: 353-5.
72. Snead OC, Hosey LC. Exacerbation of seizures in children by carbamazepine. N Engl J Med 1985; 313: 916-21.
73. Commission on classification and terminology of the International League Against Epilepsy. Proposal for revised classification of epilepsies and epileptic syndromes. Epilepsia 1989; 30: 389-99.
74. Murthy JMK, Yangala R, Srinivas M. The syndromic classification of the international league against epilepsy: A hospital-based study from South India. Epilepsia 1998; 39: 48-54.
75. Bronen RA, Fulbright RK, Spencer DD, Spencer SS, Kim JH, Lange RC, et al. Refractory epilepsy: Comparison of MR imaging, CT, and histopathologic findings in 117 patients. Radiology 1996; 201: 97-105.
76. McBride MC, Bronstein KS, Bennett B, Erba G, Pilcher W, Berg MJ. Failure of standard magnetic resonance imaging in patients with refractory temporal lobe epilepsy. Arch Neurol 1998; 55: 346-8.
77. Theodore WH, Porter RJ. Epilepsy: 100 Elementary Principles. 3 Ed. London: WB Saunders; 1995.
78. Genton P, McMenamin J. Aggravation of seizures by antiepileptic drugs: What to do in clinical practice. Epilepsia 1998; 32 (Suppl 3): S26-9.
79. Perucca E, Gram L, Avanzini G, Dulac O. Antiepileptic drugs as a cause of worsening seizures. Epilepsia 1998; 39: 5-17.
80. Cobos JE. High-dose phenytoin in the treatment of refractory epilepsy. Epilepsia 1987; 28: 111-4.
81. Ohtsuka Y, Amano R, Mizukawa M, Oka E, Ohtahara S. Treatment of intractable childhood epilepsy with high-dose valproate. Epilepsia 1992; 33: 158-64.
82. Porter RJ. How to use antiepileptic drugs. General principles. In Levy RH, Mattson RH, Meldrum BS, eds. Antiepileptic Drugs. 4 Ed. New York: Raven Press; 1995. p. 137-48.
83. Armijo JA, Cuadrado A. Bases farmacodinámicas para la asociación de antiepilépticos. Rev Neurol 1997; 25 (Supl 4): S363-73.
84. García PA, Alldredge BK. Drug-induced seizures. Neurol Clin 1994; 12: 85-99.
85. Cramer JA, Mattson RH, Prevey ML, Scheyer R, Ouellette V. How often is medication taken as prescribed? A novel assessment technique. JAMA 1989; 261: 3273-7.
86. Cramer JA. Optimizing long-term patient compliance. Neurology 1995; 45 (Suppl 1): S25-8.
87. Iriarte J, Viteri C, Artieda J. Monitorización prolongada de vídeo-EEG. Aplicaciones clínicas. Rev Neurol 1998; 26: 425-31.
88. American Electroencephalographic Society. Guideline twelve: Guidelines for long-term monitoring for epilepsy. J Clin Neurophysiol 1994; 11: 88-110.
89. Commission on classification and terminology of the International League Against Epilepsy. Proposal for revised clinical and electroencephalographic classification of epileptic seizures. Epilepsia 1981; 22: 489-501.
90. Lüders H, Acharya J, Baumgartner C, Benbadis S, Bleasel A, Burgess R, et al. Semiological seizure classification. Epilepsia 1998; 39: 1006-13.
91. Lüders H, Acharya J, Baumgartner C, Benbadis S, Bleasel A, Burgess R, et al. A new epileptic seizure classification based exclusively on ictal semiology. Acta Neurol Scand 1999; 99: 137-41.
92. Fernández-Torre JL, Alarcón G, Binnie CD, Polkey CE. Comparison of sphenoidal, foramen ovale and anterior temporal placements for detecting interictal epileptiform discharges in presurgical assessment for temporal lobe epilepsy. Clin Neurophysiol 1999; 110: 895-904.
93. Parra J, Iriarte J. Valor del registro ictal con video-EEG en la evaluación prequirúrgica de pacientes con epilepsia del lóbulo temporal. Semiología y patrones electroencefalográficos. Rev Neurol 1999; 28: 898-908.
94. Sperling MR. Clinical challenges in invasive monitoring in epilepsy surgery. Epilepsia 1997; 38 (Suppl 4): S6-12.
95. Galdón A, López M, Casquero A, Piñero M, Paniagua J. Protocolo de evaluación neurofisiológica prequirúrgica en epilepsia resistente a tratamiento. Rev Neurol 1999; 28: 593-600.
96. Parra J, Kanner AM, Iriarte J, Gil-Nagel A. When should induction protocols be used in the diagnostic evaluation of patients with paroxysmal events? Epilepsia 1998; 39: 863-7.
97. Yen DJ, Chen C, Shih YH, Guo YC, Liu LT, Yu HY, et al. Antiepileptic drug withdrawal in patients with temporal lobe epilepsy undergoing presurgical video-EEG monitoring. Epilepsia 2001; 42: 251-5.
98. So EL, Fisch BJ. Drug withdrawal and other activating techniques. In Engel J Jr, Pedley TA, eds. Epilepsy: A Comprehensive Textbook. Philadelphia: Lippincott-Raven; 1997. p. 1021-7.
99. Duncan JS. Imaging and epilepsy. Brain 1997; 120: 339-77.
100. ILAE Commission Report. Guidelines for neuroimaging evaluation of patients with uncontrolled epilepsy considered for surgery. Epilepsia 1998; 39: 1375-6.
101. Kuzniecky RI, Jackson GD, eds. Magnetic Resonance in Epilepsy. New York: Raven Press; 1995.
102. Lee DH, Gao FQ, Rogers JM, Gulka I, Mackenzie IR, Parrent AG, et al. MR in temporal lobe epilepsy: Analysis with pathologic confirmation. Am J Neuroradiol 1998; 19: 19-27.
103. Bronen RA, Fulbright RK, Spencer DD, Spencer SS, Kim JH, Lange RC. MR characteristics of neoplasms and vascular malformations associated with epilepsy. Magn Reson Imaging 1995; 13: 1153-62.
104. Shorvon S. MRI of cortical dysgenesis. Epilepsia 1997; 38 (Suppl 10): S13-8.
105. Lehéricy S, Semah F, Hasboun D, Dormont D, Clémenceau S, Granat O, et al. Temporal lobe epilepsy with varying severity: MRI study of 222 patients. Neuroradiology 1997; 39: 788-96.
106. Sánchez-Álvarez JC, Pastor-Pons E, García-Gómez T, Escamilla F, Galdón A, Busquier H, et al. El diagnóstico de la esclerosis temporal mesial mediante imagen de resonancia magnética. Rev Neurol 2000; 31: 701-11.
107. Thadani VM, Williamson PD, Berger R, Spencer SS, Spencer DD, Novelly RA, et al. Successful epilepsy surgery without intracranial EEG recording: Criteria for patient selection. Epilepsia 1995; 36: 7-15.
108. Holmes MD, Dodrill CB, Ojemann LM, Ojemann GA. Five-year outcome after epilepsy surgery in nonmonitored and monitored surgical candidates. Epilepsia 1996; 37: 748-52.
109. Mattson RH. Antiepileptic drug monitoring: A reappraisal. Epilepsia 1995; 36 (Suppl 5): S22-9.
110. 99mTc-ethyl cysteinate dimer single photon emission computed tomography in patients with refractory partial epilepsy. Epilepsia 1997; 38: 466-71.
111. 99mTc-ethil cysteinate dimer in patients with medically refractory epilepsy. Epilepsia 1999; 40: 693-702.
112. Carreras JL, Pérez MJ, Montz R, Maldonado A, Gorospe E. La tomografía por emisión de positrones en el estudio de las epilepsias. Rev Neurol 1997; 25 (Supl 4): S418-23.
113. Duncan JS. Positron emission tomography studies of cerebral blood flow and glucose metabolism. Epilepsia 1997; 38 (Suppl 10): S42-7.
114. Lee CC, Ward HA, Sharbrough FW, Meyer FB, Marsh WR, Raffel C, et al. Assessment of functional MR imaging in neurosurgical planning. Am J Neuroradiol 1999; 20: 1511-9.
115. Krakow K, Woermann FG, Symms MR, Allen PJ, Lemieux L, Barker GJ, et al. EEG-triggered functional MRI of interictal epileptiform activity in patients with partial seizures. Brain 1999; 122: 1679-88.
116. Kwan P, Brodie MJ. Neuropsychological effects of epilepsy and antiepileptic drugs. Lancet 2001; 357: 216-22.
117. Loring DW. Neuropsychological evaluation in epilepsy surgery. Epilepsia 1997; 38 (Suppl 4): S18-23.
118. Maestú F, Martin P, Gil-Nagel A, Franch O, Sola RG. Evaluación en la cirugía de la epilepsia. Rev Neurol 2000; 30: 477-82.
119. Stagno SJ. Psychiatric aspects of epilepsy. In Wyllie E, ed. The Treatment of Epilepsies. 3 Ed. Philadelphia: Lippincott Williams & Wilkins; 2001. p. 1227-42.
120. Harris EC, Barraclough B. Suicide as an outcome for mental disorders. A meta-analysis. Br J Psychiatry 1997; 170: 205-28.
121. Buchanan N, Snars J. Pseudoseizures (non epileptic attack disorder): Clinical management and outcome in 50 patients. Seizure 1993; 2: 141-6.
122. Achten E. Aspects of proton MR spectroscopy in the seizure patient. Neuroimaging Clin N Am 1998; 8: 849-62.
123. Li LM, Cendes F, Antel SB, Andermann F, Serles W, Dubeau F, et al. Prognostic value of proton magnetic resonance spectroscopic imaging for surgical outcome in patients with intractable temporal lobe epilepsy and bilateral hippocampal atrophy. Ann Neurol 2000; 47: 195-200.
124. Maestú C, Gómez E, Piñeiro R, Sola RG. Magnetoencefalografía: Una nueva técnica de diagnóstico funcional en neurociencia. Rev Neurol 1999; 28: 1077-90.
125. Parra J, Velis DN. Nuevas técnicas en Neurofsiología: Magnetoencefalografía. Contribuciones de la magnetoencefalografía al estudio de la epilepsia. Rev Neurol 2000; 30: 364-70.
126. Shorvon S. The drug treatment of epilepsy. In Hopskins A, Shorvon S, Cascino G, eds. Epilepsy. 2 Ed. London: Chapman and Hall; 1995. p. 171-214.
127. Ferrendelli JA. Use of rational polypharmacy to treat epilepsy. In Homan RW, Leppik IE, Lothman EW, Penry JK, Theodore WH, eds. Rational Polypharmacy. Amsterdam: Elsevier; 1996. p. 239-43.
128. Chadwick D. Tratamiento farmacológico racional de la epilepsia. In Porter RJ, Chadwick D, eds. Epilepsias 2. Edición Española. Barcelona: Temis Pharma; 1998. p. 261-81.
129. Arroyo S, Campistol J, Comes E, Fossas P, Martinez I, Padró L, et al. El tratamiento de la epilepsia. Guía terapéutica de la Sociedad Catalana de Neurología. Rev Neurol 1999; 29: 754-66.
130. Reynolds EH, Shorvon SD. Mono-or polytherapy of epilepsy? Epilepsia 1981; 22: 1-10.
131. Schmidt D. Single drug therapy for intractable epilepsy. J Neurol 1983; 229: 221-6.
132. Leppik IE. Monotherapy and polypharmacy. Neurology 2000; 55 (Suppl 3): S25-9.
133. Elger CE, Bauer J, Scherrmann J, Widman G. Aggravation of focal epileptic seizures by antiepileptic drugs. Epilepsia 1998; 39 (Suppl 3): S15-8.
134. Mattson RH, Cramer JA, Collins JF, Smith DB, Delgado-Escueta AV, Browne TR, et al. Comparison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondary generalized tonic-clonic seizures. N Engl J Med 1985; 313: 145-51.
135. Ramsay RE, Wilder BJ, Berger JR, Bruni J. A double-blind study comparing carbamazepine with phenytoin as initial seizure therapy in adults. Neurology 1983; 33: 904-10.
136. Mattson RH, Cramer JA, Collins JF. Comparison of valproate with carbamazepine for the treatment of complex partial seizures and secondary generalized tonic-clonic seizures in adults. N Engl J Med 1992; 327: 765-71.
137. Heller AJ, Chesterman P, Elwes RDC, Crawford P, Chadwick D, Johnson AL, et al. Phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed adult epilepsy: A randomized comparative monotherapy trial. J Neurol Neurosurg Psychiatry 1995; 58: 44-50.
138. Wilder BJ. Therapeutic strategies for the treatment of epilepsy. In Thomas RB Jr, ed. Emerging Therapies for Early Seizure Control in Epilepsy. New York: Memorial Institute for Continuing Medical Education; 2000. p. 19-26.
139. Marson AG, Williamson PR, Hutton JL, Clough HE, Chadwick DW. Carbamazepine versus valproate monotherapy for epilepsy. Cochrane Database Syst Rev 2000; 3: CD001030.
140. Kalviainen R, Aika M, Saukknen AM, Mervaala E, Riekkinen PJ Sr. Vigabatrin vs carbamazepine monotherapy in patients with newly diagnosed epilepsy. A randomized, controlled study. Arch Neurol 1995; 52: 989-96.
141. Tanganelli P, Regesta G. Vigabatrin vs carbamazepine monotherapy in newly diagnosed focal epilepsy: A randomized response conditional cross-over study. Epilepsy Res 1996; 25: 257-62.
142. Zamponi N, Cardinalli G. Open comparative long-term study of vigabatrin vs carbamazepine in newly diagnosed partial seizures in children. Arch Neurol 1999; 56: 605-7.
143. Chadwick D. Safety and efficacy of vigabatrin and carbamazepine in newly diagnosed epilepsy: A multicenter randomised double-blind study. Vigabatrin European monotherapy study group. Lancet 1999; 354: 13-9.
144. Brodie MJ, Richens A, Yuen AW. The UK lamotrigine/carbamazepine monotherapy trial group: Double blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. Lancet 1995; 345: 476-9.
145. Reunanen M, Dam M, Yuen AW. A randomized open multicentre comparative trial of lamotrigine and carbamazepine as monotherapy in patients with newly diagnosed or recurrent epilepsy. Epilepsy Res 1996; 23: 149-55.
146. Brodie MJ, Overstall PW, Giorgi L. Multicentre double-blind, randomised comparison between lamotrigine and carbamazepine in elderly patients with newly diagnosed epilepsy. The UK Lamotrigine Elderly Study Group. Epilepsy Res 1999; 37: 81-7.
147. Chadwick DW, Anhut H, Greiner MJ, Alexander J, Murray GH, Garofalo EA, et al. A double-blind trial of gabapentin monotherapy for newly diagnosed partial seizures, International Gabapentin Monotherapy Study Group 945-77. Neurology 1998; 51: 1282-8.
148. Dam M, Ekberg R, Loyning Y, Waltimo O, Jakobsen K. A double blind study comparing oxcarbazepine and carbamazepine in patients with newly diagnosed, previously untreated epilepsy. Epilepsy Res 1989; 3: 70-6.
149. Privitera MD, Brodie MJ, Neto W, Wang S. Topiramate vs. investigator choice of carbamacepine or valproate as monotherapy in newly diagnosed epilepsy. Epilepsia 2000; 41 (Suppl 7): S93-4.
150. Arroyo S, Sander JWAS. Carbamazepine in comparative trials: Pharmacokinetics characteristics too often forgotten. Neurology 1999; 53: 1170-4.
151. Sachdeo R, Beydoun A, Schachter S, Vazquez B, Schaul N, Mesenbrink P, et al. Oxcarbazepine (Trileptal) as monotherapy in patients with partial seizures. Neurology 2001; 57: 864-71.
152. Mattson RH. Medical management of epilepsy in adults. Neurology 1998; 51 (Suppl. 4): 815-20.
153. Gericke CA, Picard F, de Saint-Martin A, Strumia S, Marescaux C, Hirsch E. Efficacy of lamotrigine in idiopathic generalized epilepsy syndromes: A video-EEG-controlled, open study. Epileptic Disord 1999; 1: 159-65.
154. Mauri-Llerda JA, Tejero-Juste C, Íñiguez C, Morales-Asín F. Utilidad de la lamotrigina en el tratamiento de las crisis epilépticas de ausencia. Rev Neurol 2001; 32: 247-50.
155. Beran RG, Berkovic SF, Dunagan FM, Vajda FJ, Danta G, Black AB, et al. Double-blind, placebo-controlled, crossover study of lamotrigine intreatment-resistant generalised epilepsy. Epilepsia 1998; 39: 1329-33.
156. Motte J, Trevathan E, Arvidsson JF, Barrera MN, Mullens EL, Manasco P. Lamotrigine for generalized seizures associated with the Lennox-Gastaut syndrome. Lamictal Lennox-Gastaut Study Group. N Engl J Med 1997; 337: 1807-12.
157. Montouris GD, Biton V, Rosenfeld WE. Nonfocal generalized tonic-clonic seizures: Response during long-term topiramate treatment. Topiramate YTC/YTCE Study Group. Epilepsia 2000; 41 (Suppl 1): S77-81.
158. Glauser TA, Levisohn PM, Ritter F, Sachdeo RC. Topiramate in Lennox-Gastaut syndrome: Open-label treatment of patients completing a randomized controlled trial. Topiramate YL Study Group. Epilepsia 2000; 41 (Suppl 1): S86-90.
159. Perucca E. The management of refractory idiopathic epilepsies. Epilepsia 2001; 42 (Suppl 3): S31-5.
160. Serratosa JM. Myoclonic seizures. In Willye E, ed. The Treatment of Epilepsies. 3 Ed. Philadelphia: Lippincott Williams & Wilkins; 2001. p. 395-404.
161. Genton P, Guerrini R, Remi C. Piracetam in the treatment of cortical myoclonus. Pharmacopsychiatry 1999; 32 (Suppl 1): S49-53.
162. Brodie MJ, French JA. Management of epilepsy in adolescents and adults. Lancet 2000; 356: 323-9.
163. Lesser RP, Pippenger CE, Lüders H, Dinner DS. High-dose monotherapy in treatment of intractable seizures. Neurology 1984; 34: 707-11.
164. Kwan P, Brodie MJ. Effectiveness of first antiepileptic drug. Epilepsia 2001; 42: 1255-60.
165. Mattson RH. Current challenges in the treatment of epilepsy. Neurology 1994; 44 (Suppl 5): S4-9.
166. Perucca E. Innovative monotherapy trial designs for the assessment of antiepileptic drugs: A critical appraisal. Eur J Clin Pharmacol 1998; 54: 1-5.
167. Faught E, Sachdeo RC, Remler MP, Chayasirisobhon S, Iragui-Madoz VJ, Ramsay RE, et al. Felbamate monotherapy for partial-onset seizures: An active-control trial. Neurology 1993; 43: 688-92.
168. French J, Smith M, Faught E, Brown L. Practice advisory: The use of felbamate in the treatment of patients with intractable epilepsy: Report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology 1999; 52: 1540-5.
169. Malmgren K, Ben-Menachem E, Frisen L. Vigabatrin visual toxicity: Evolution and dose dependence. Epilepsia. 2001; 42: 609-15.
170. Deckers CL, Hekster YA, Keyser A, Meinardi H, Renier WO. Reappraisal of polytherapy in epilepsy: A critical review of drug load and adverse effects. Epilepsia 1997; 38: 570-75.
171. Willmore LJ, Shu V, Wallin B. Efficacy and safety of add-on divalproex sodium in the treatment of complex partial seizures. The M88-194 Study Group. Neurology 1996; 46: 49-53.
172. Walker MC, Li LM, Sander JW. Long term use of lamotrigine and vigabatrin in severe refractory epilepsy: Audit of outcome. Br Med J 1996; 313: 1184-5.
173. Marson AG, Kadir ZA, Hutton JL. The new antiepileptic drugs: A systematic review of their efficacy and tolerability. Epilepsia 1997; 38: 859-80.
174. Cramer JA, Fisher R, Ben-Menachen E, French J, Mattson RH. New antiepileptic drugs: Comparison of key clinical trials. Epilepsia 1999; 40: 590-600.
175. Montenegro MA, Cendes F, Noronha AL, Mory SB, Carvalho MI, Marques LH, et al. Efficacy of clobazam as add-on therapy in patients with refractory partial epilepsy. Epilepsia 2001; 42: 539-42.
176. Elger CE, Fernández G. Options after the first antiepileptic drug has failed. Epilepsia 1999; 40 (Suppl 6): S9-12.
177. O'Donoghue MF, Sander JW. How rational is current anti-epileptic drug treatment? Rev Neurol (Paris) 1997; 153 (Suppl 1): S25-8.
178. Rowan AJ, Meijer JW, de Beer-Pawlikowski N, van der Geest P, Meinardi H. Valproate-ethosuximide combination therapy for refractory absence seizures. Arch Neurol 1983; 40: 797-802.
179. Brodie MJ, Yuen AW. Lamotrigine substitution study: Evidence for synergism with sodium valproate? 105 Study Group. Epilepsy Res 1997; 26: 423-32.
180. Pisani F, Oteri G, Russo MF, Di Perri R, Perucca E, Richens A. The efficacy of valproate-lamotrigine comedication in refractory complex partial seizures: Evidence for a pharmacodynamic interaction. Epilepsia 1999; 40: 1141-6.
181. Meinardi H. Use of combined antiepileptic drug therapy. In Levy RH, Mattson RH, Meldrum BS, eds. Antiepileptic Drugs. 4 Ed. New York: Raven Press; 1995. p. 91-7.
182. Engel J Jr. Update on surgical treatment of the epilepsies. Summary of the second international Palm Desert conference on the surgical treatment of the epilepsies (1992). Neurology 1993; 43: 1612-7.
183. ILAE commission report. A global survey on epilepsy surgery, 1980-1990: A report by the commission on neurosurgery of epilepsy, The International League Against Epilepsy. Epilepsia 1997; 38: 249-55.
184. González J, García L, Conde JL. Informe sobre la ciragía de la epilepsia. Rev Neurol 1999; 29: 680-92.
185. Binnie CD, Polkey ChE. Commission on Neurosurgery of the International League Against Epilepsy (ILAE) 1993-1997: Recommended Standards. Epilepsia 2000; 41: 1346-9.
186. Pre-surgical evaluation for epilepsy surgery. European standards. European Federation of Neurological Societies Task Force. Eur J Neurol 2000; 7: 119-22.
187. Spencer SS. Long-term outcome after epilepsy surgery. Epilepsia 1996; 37: 807-13.
188. Viteri C, Iriarte J, Schlumberger E, Manrique M. Tratamiento quirúrgico de las epilepsias: Criterios de selección de pacientes y resultados. Rev Neurol 2000; 30 (Suppl. 1): S141-53.
189. Wass CT, Rajala MM, Hughes JM, Sharbrough FW, Offord KP, Rademacher DM, et al. Long-term follow-up of patients treated surgically for medically intractable epilepsy: Results in 291 patients treated at Mayo Clinic Rochester between July 1972 and March 1985. Mayo Clin Proc 1996; 71: 1105-13.
190. Selai CE, Elstner K, Trimble MR. Quality of life pre and post epilepsy surgery. Epilepsy Res 2000; 38: 67-74.
191. Behrens E, Schramm J, Zentner J, König R. Surgical and neurological complications in a series of 708 epilepsy surgery procedures. Neurosurgery 1997; 41: 1-10.
192. Rydenhag B, Silander HC. Complications of epilepsy surgery after 654 procedures in Sweden, September 1990-1995: A multicenter study based on the Swedish National Epilepsy Surgery Register. Neurosurgery 2001; 49: 51-6.
193. Jones MW, Andermann F. Temporal lobe epilepsy surgery: Definition of candidacy. Can J Neurol Sci 2000; 27 (Suppl 1): S11-3.
194. Wieser HG, Burcet J, Russi A. Indicaciones del tratamiento quirúrgico de la epilepsia. Rev Neurol 2000; 30: 1190-6.
195. Engel J, Cascino GD, Shields WD. Surgically remediable syndromes. In Engel J Jr, Pedley TA, eds. Epilepsy: A Comprehensive Textbook. Philadelphia: Lippincott-Raven Publishers; 1997. p. 1687-96.
196. Serrano PJ, Sánchez JC, García T. Esclerosis temporal mesial (I): Datos histológicos, hipótesis fisiopatológicas y factores etiológicos. Rev Neurol 1997; 25: 584-9.
197. Serrano PJ, Sánchez JC, Garcia T. Esclerosis temporal mesial (II): Manifestaciones clínicas y estudios complementarios. Rev Neurol 1998; 26: 592-7.
198. Bell BD, Davies KG. Anterior temporal lobectomy, hippocampal sclerosis, and memory: Recent neuropsychological findings. Neuropsychol Rev 1998; 8: 25-41.
199. Kälviäinen R, Salmenperä T, Partanen K, Vainio P, Riekkinen P, Pitkänen A. Recurrent seizures may cause hippocampal damage in temporal lobe epilepsy. Neurology 1998; 50: 1377-82.
200. Tasch E, Cendes F, Li LM, Dubeau F, Andermann F, Arnold DL. Neuroimaging evidence of progressive neuronal loss and disfunction in temporal lobe epilepsy. Ann Neurol 1999; 45: 568-76.
201. Hsu Y, Chang C, Chang C-N, Chu N-S, Lim K-E, Hsu J-C. Proton MR spectroscopy in patients with complex partial seizures: Single-voxel spectroscopy versus chemical-shift imaging. Am J Neuroradiol 1999; 20: 643-51.
202. Fuerst D, Shah J, Kupsky WJ, Johnson R, Shah A, Hayman-Abello, et al. Volumetric MRI, pathological, and neuropsychological progression in hippocampal sclerosis. Neurology 2001; 57: 184-8.
203. Sperling MR, O'Connor MJ, Saykin AJ, Plummer C. Temporal lobectomy for refractory epilepsy. JAMA 1996; 276: 470-5.
204. Salanova V, Markand O, Worth R. Longitudinal follow-up in 145 patients with medically refractory temporal lobe epilepsy treated surgically between 1984 and 1995. Epilepsia 1999; 40: 1417-23.
205. Wiebe S, Blume WT, Girvin JP, Eliasziw M. A randomized, controlled trial of surgery for temporal-lobe epilepsy. N Engl J Med 2001; 345: 311-8.
206. Engel J Jr. The timing of surgical intervention for mesial temporal lobe epilepsy. A plan for a randomized clinical trial. Arch Neurol 1999; 56: 1338-41.
207. Sutula T. Progression in mesial temporal lobe epilepsy [editorial]. Ann Neurol 1999; 45: 553-6.
208. Engel J Jr. Finally, a randomized, controlled trial of epilepsy surgery [editorial]. N Engl J Med 2001; 345: 365-6.
209. Dlugos DJ. The early identification of candidates for epilepsy surgery. Arch Neurol 2001; 58: 1543-6.
210. Kutsy RL. Focal extratemporal epilepsy: Clinical features, EEG patterns, and surgical approach. J Neurol Sci 1999; 166: 1-15.
211. Schramm J, Kral T, Blumcke I, Elger CE. Surgery for neocortical temporal and frontal epilepsy. Adv Neurol 2000; 84: 595-603.
212. Sisodiya SM. Surgery for malformations of cortical development causing epilepsy. Brain 2000; 123: 1075-91.
213. Villemure JG, Peacock W. Multilobar resections and hemispherectomy. In Engel J Jr, Pedley TA, eds. Epilepsy: A Comprehensive Textbook. Philadelphia: Lippincott-Raven Publishers; 1997. p. 1829-39.
214. Mínguez-Castellanos A, Sánchez-Álvarez JC, Altuzarra A, Serrano-Castro PJ, Hernández-Ramos FJ, Gómez-Camello A, et al. La callosotomía en el tratamiento de la epilepsia farmacorresistente. Rev Neurol 1996; 24: 539-48.
215. Lee SA, Spencer DD, Spencer SS. Intracranial EEG seizure-onset patterns in neocortical epilepsy. Epilepsia 2000; 41: 297-307.
216. Foldvary N, Bingaman WE, Wyllie E. Surgical treatment of epilepsy. Neurol Clin 2001; 19: 491-515.
217. Rosenow F, Lüders H. Presurgical evaluation of epilepsy. Brain 2001; 124: 1683-700.
218. So EL. Integration of EEG, MRI, and SPECT in localizing the seizure focus for epilepsy surgery. Epilepsia 2000; 41 (Suppl 3): S48-54.
219. Moser DJ, Bauer RM, Gilmore RL, Dede DE, Fennell EB, Algina JJ, et al. Electroencephalographic, volumetric, and neuropsychological indicators of seizure focus lateralization in temporal lobe epilepsy. Arch Neurol 2000; 57: 707-12.
220. Diehl B, Lüders HO. Temporal lobe epilepsy: When are invasive recordings needed? Epilepsia 2000; 41 (Suppl 3): S61-74.
221. Janszky J, Jokeit H, Schulz R, Hoppe M, Ebner A. EEG predicts surgical outcome in lesional frontal lobe epilepsy. Neurology 2000; 54: 1470-6.
222. Engel J Jr. Overview of functional neuroimaging in epilepsy. Adv Neurol 2000; 83: 1-9.
223. Neuroimaging Subcommission of the International League Against Epilepsy. Commission on Diagnostic Strategies: Recommendations for functional neuroimaging of persons with epilepsy. Epilepsia 2000; 41: 1350-6.
224. Cascino GD. Advances in neuroimaging: Surgical localization. Epilepsia 2001; 42: 3-12.
225. McIntosh AM, Wilson SJ, Berkovic SF. Seizure outcome after temporal lobectomy: Current research practice and findings. Epilepsia 2001; 42: 1288-307.
226. Spencer DD, Ojeman GA. Overview of therapeutic procedures. In Engel J Jr, ed. Surgical Treatment of the Epilepsies. New York: Raven Press; 1993. p. 455-71.
227. Wyler AR, Hermann BP, Somes G. Extent of medial temporal resection on outcome from anterior temporal lobectomy: A randomized prospective study. Neurosurgery 1995; 37: 982-91.
228. Arruda F, Cendes F, Andermann F, Dubeau F, Villemure J, Jones-Gotman M, et al. Mesial atrophy and outcome after amygdalohippocampectomy or temporal lobe removal. Ann Neurol 1996; 40: 446-50.
229. Schramm J, Kral T, Grunwald T, Blumcke I. Surgical treatment for neocortical temporal lobe epilepsy: Clinical and surgical aspects and seizure outcome. J Neurosurg 2001; 94: 33-42.
230. Hennessy MJ, Elwes RD, Honavar M, Rabe-Hesketh S, Binnie CD, Polkey CE. Predictors of outcome and pathological considerations in the surgical treatment of intractable epilepsy associated with temporal lobe lesions. J Neurol Neurosurg Psychiatry 2001; 70: 450-8.
231. Li LM, Cendes F, Andermann F, Watson C, Fish DR, Cook MJ, et al. Surgical outcome in patients with epilepsy and dual pathology. Brain 1999; 122: 799-805.
232. Holmes MD, Born DE, Kutsy RL, Wilensky AJ, Ojemann GA, Ojemann LM. Outcome after surgery in patients with refractory temporal lobe epilepsy and normal MRI. Seizure 2000; 9: 407-11.
233. Frater JL, Prayson RA, Morris III HH, Bingaman WE. Surgical pathologic findings of extratemporal-based intractable epilepsy: A study of 133 consecutive resections. Arch Pathol Lab Med 2000; 124: 545-9.
234. Clarke DB, Olivier A, Andermann F, Fish D. Surgical treatment of epilepsy: The problem of lesion/focus incongruence. Surg Neurol 1996; 46: 579-85.
235. Morrell F, Kanner AM, de Toledo-Morrell L, Hoeppner T, Whisler WW. Multiple subpial transection. Adv Neurol 1999; 81: 259-70.
236. Villemure JG, Vernet O, Delalande O. Hemispheric disconnection: Callosotomy and hemispherectomy. Adv Tech Stand Neurosurg 2000; 26: 25-78.
237. Spencer SS, Spencer DD, Sass K, Westerveld M, Katz A, Mattson R. Anterior, total, and two-stage Corpus Callosum Section: Differential and incremental seizure responses. Epilepsia 1993; 34: 561-7.
238. Smith MC, Byrne R. Multiple subpial transection in neocortical epilepsy: Part I. Adv Neurol 2000; 84: 621-34.
239. Wyler AR. Multiple subpial transections in neocortical epilepsy: Part II. Adv Neurol 2000; 84: 635-42.
240. Mulligan LP, Spencer DD, Spencer SS. Multiple subpial transections: The Yale experience. Epilepsia 2001; 42: 226-9.
241. Lunsford LD, Kondziolka D, Flickinger JC. Stereotactic radiosurgery: Current spectrum and results. Clin Neurosurg 1992; 38: 405-44.
242. Kurita H, Kawamoto S, Suzuki I, Sasaki T, Tago M, Terahara A, et al. Control of epilepsy associated with cerebral arteriovenous malformations after radiosurgery. J Neurol Neurosurg Psychiatry 1998; 65: 648-55.
243. Regis J, Bartolomei F, Rey M, Hayashi M, Chauvel P, Peragut JC. Gamma knife surgery for mesial temporal lobe epilepsy. J Neurosurg 2000; 93 (Suppl 3): S141-6.
244. Regis J, Bartolomei F, Hayashi M, Roberts D, Chauvel P, Peragut JC. The role of gamma knife surgery in the treatment of severe epilepsies. Epileptic Disord 2000; 2: 113-22.
245. Binnie CD. Vagus nerve stimulation for epilepsy: A review. Seizure 2000; 9: 161-9.
246. Vagus Nerve Stimulation Study Group. A randomized controlled trial of chronic vagus nerve stimulation for treatment of medically intractable seizures. Neurology 1995; 45: 224-30.
247. Handforth A, DeGiorgio CM, Schachter SC, Uthman BM, Naritoku DK, Tecoma ES, et al. Vagus nerve stimulation therapy for partial-onset seizures: A randomized active-control trial. Neurology 1998; 51: 48-55.
248. Morris GL, Mueller WM. Long-term treatment with vagus nerve stimulation in patients with refractory epilepsy. The Vagus Nerve Stimulation Study Group E01-E05. Neurology 1999; 53: 1731-5.
249. Tatum WO, Moore DB, Stecker MM, Baltuch GH, French JA, Ferreira JA, et al. Ventricular asystole during vagus nerve stimulation for epilepsy in humans. Neurology 1999; 52: 1267-9.
250. Fisher RS, Handforth A. Reassessment: Vagus nerve stimulation for epilepsy. A Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 1999; 53: 666-9.
251. Reiss WG, Oles KS. Acetazolamide in the treatment of seizures. Ann Pharmacother 1996; 30: 514-9.
252. Lim LL, Foldvary N, Mascha E, Lee J. Acetazolamide in women with catamenial epilepsy. Epilepsia 2001; 42: 746-9.
253. Klein P, Herzog AG. Hormonal effects on epilepsy in women. Epilepsia 1998; 39 (Suppl 8): S9-16.
254. Herzog AG. Progesterone therapy in women with epilepsy: A 3-year follow-up. Neurology 1999; 52: 1917-8.
255. Aarli JA. Epilepsy and the immune system. Arch Neurol 2000; 57: 1689-92.
256. van Rijckevorsel-Harmant K, Delire M, Schmitz-Moorman W, Wieser HG. Treatment of refractory epilepsy with intravenous immunoglobulins. Results of the first double-blind/dose finding clinical study. Int J Clin Lab Res 1994; 24: 162-6.
257. van Engelen BG, Renier WO, Weemaes CM, Gabreels FJ, Meinardi H. Immunoglobulin treatment in epilepsy, a review of the literature. Epilepsy Res 1994; 19: 181-90.
258. Vining EP. Clinical efficacy of the ketogenic diet. Epilepsy Res 1999; 37: 181-90.
259. Maydell BV, Wyllie E, Akhtar N, Kotagal P, Powaski K, Cook K, et al. Efficacy of the ketogenic diet in focal versus generalized seizures. Pediatr Neurol 2001; 25: 208-12.
260. Hemingway C, Freeman JM, Pillas DJ, Pyzik PL. The ketogenic diet: A 3- to 6-year follow-up of 150 children enrolled prospectively. Pediatrics 2001; 108: 898-905.
261. Sirven J, Whedon B, Caplan D, Liporace J, Glosser D, O'Dwyer J, et al. The ketogenic diet for intractable epilepsy in adults: Preliminary results. Epilepsia 1999; 40: 1721-6.
262. Stoffel-Wagner B, Bauer J, Flugel D, Brennemann W, Klingmuller D, Elger CE. Serum sex hormones are altered in patients with chronic temporal lobe epilepsy receiving anticonvulsant medication. Epilepsia 1998; 39: 1164-73.
263. Canger R, Battino D, Canevini MP, Fumarola C, Guidolin L, Vigmoli A, et al. Malformations in offspring of women with epilepsy: A prospective study. Epilepsia 1999; 40: 1231-6.
264. Crawford PM, Oxbury JM. Adverse events during long-term medical treatment: Adults. In Oxbury J, Polkey C, Duchowny M, eds. Intractable Focal Epilepsy. London: Harcourt Publishers; 2000. p. 537-44.
265. Vermeulen J, Aldenkamp AP. Cognitive side-effects of chronic antiepileptic drug treatment: A review of 25 years of research. Epilepsy Res 1995; 22: 65-95.
266. Devinsky O, Baker G, Cramer J. Quantitative measures of assessment. In Engel J Jr, Pedley TA, eds. Epilepsy: A Comprehensive Textbook. Philadelphia: Lippincott-Raven; 1997. p. 1107-13.
267. Callaghan N, O'Dwyer R, Keating J. Unnecessary polypharmacy in patients with frequent seizures. Acta Neurol Scand 1984; 69: 15-9.
268. Ure JA, Perassolo M. Update on the pathophysiology of the epilepsies. J Neurol Sci 2000; 177: 1-17.
269. Dalby NO, Mody I. The process of epileptogenesis: A pathophysiological approach. Curr Opin Neurol 2001; 14: 187-92.
270. Dichter MA. Basic mechanisms of epilepsy: Targets for therapeutic intervention. Epilepsia 1997; 38 (Suppl 9): S2-6.
271. Chapman AG. Glutamate receptors in epilepsy. Prog Brain Res 1998; 116: 371-83.
272. McBain CJ, Mayer ML. N-methyl-D-aspartic acid receptor structure and function. Physiol Rev 1994; 74: 723-60.
273. Schachter SC, Tarsy D. Remacemide: Current status and clinical applications. Exp Opin Investig Drugs 2000; 9: 871-83.
274. Bialer M, Johannessen SI, Kupferberg HJ, Levy RH, Loiseau P, Perucca E. Progress report on new antiepileptic drugs: A summary of the Fifth Eilat Conference (EILAT V). Epilepsy Res 2001; 43: 11-58.
275. Bauer J, Dienel A, Elger CE, and Losigamone Study Group. Losigamone add-on therapy in partial epilepsy: A placebo-controlled study. Acta Neurol Scand 2001; 103: 226-30.
276. Nicolson A, Leach JP. Future prospects for the drug treatment of epilepsy. CNS Drugs 2001; 15: 955-68.
277. B receptor antagonists. Arzneimittelforschung 1998; 48: 797-801.
278. Bowery NG, Parry K, Boehrer A, Mathivet P, Marescaux C, Bernasconi R. Pertussis toxin decreases absence seizures and GABA(B) receptor binding in thalamus of a genetically prone rat (GAERS). Neuropharmacology 1999; 38: 1691-7.
279. Gasior M, Carter RB, Goldberg SR, Witkin JM. Anticonvulsant and behavioral effects of neuroactive steroids alone and in conjunction with diazepam. J Pharmacol Exp Ther 1997; 282: 543-53.
280. Carter RB, Wood PL, Wieland S, Hawkinson JE, Belelli D, Lambert JJ, et al. Characterization of the anticonvulsant properties of ganaxolone (CCD 1042; 3-alpha-hydroxy-3-beta-methyl-5-alpha-pregnan-20-one), a selective, high-affinity, steroid modulator of the gamma-aminobutyric acid (A) receptor. J Pharmacol Exp Ther 1997; 280: 1284-95.
281. Bialer M, Johannessen SI, Kupferberg HJ, Levy RH, Loiseau P, Perucca E. Progress report on new antiepileptic drugs: A summary of the fourth Eilat conference (EILAT IV). Epilepsy Res 1999; 34: 1-41.
282. Kerrigan JF, Shields WD, Nelson TY, Bluestone DL, Dodson WE, Bourgeois BF, et al. Ganaxolone for treating intractable infantile spasms: A multicenter, open-label, add-on trial. Epilepsy Res 2000; 42: 133-9.
283. Czuczwar SJ, Patsalos PN. The new generation of GABA enhancers. Potential in the treatment of epilepsy. CNS Drugs 2001; 15: 339-50.
284. Roettger VR, Amara SG. GABA and glutamate transporters: Therapeutic and etiologic implications for epilepsy. Adv Neurol 1999; 79: 551-60.
285. Conti F, de Biasi S, Minelli A, Rothstein JD, Melone M. EAAC1, a high-affinity glutamate transporter, is localized to astrocytes and gabaergic neurons besides pyramidal cells in the rat cerebral cortex. Cereb Cortex 1998; 8: 108-16.
286. Wickenden AD, Yu W, Zou A, Jegla T, Wagoner PK. Retigabine, a novel anti-convulsant, enhances activation of KCNQ2/Q3 potassium channels. Mol Pharmacol 2000; 58: 591-600.
287. Zhang LX, Li XL, Smith MA, Post RM, Han JS. Lipofectin-facilitated transfer of cholecystokinin gene corrects behavioral abnormalities of rats with audiogenic seizures. Neuroscience 1997; 77: 15-22.
288. O'Connor WM, Davidson BL, Kaplitt MG, Abbey MV, During MJ, Leone P, et al. Adenovirus vector-mediated gene transfer into human epileptogenic brain slices: Prospects for gene therapy in epilepsy. Exp Neurol 1997; 148: 167-78.
289. Freese A, Kaplitt MG, O'Connor WM, Abbey M, Langer D, Leone P, et al. Direct gene transfer into human epileptogenic hippocampal tissue with an adeno-associated virus vector: Implications for a gene therapy approach to epilepsy. Epilepsia 1997; 38: 759-66.
290. During MJ, Symes CW, Lawlor PA, Lin J, Dunning J, Fitzsimons HL, et al. An oral vaccine against NMDAR1 with efficacy in experimental stroke and epilepsy. Science 2000; 287: 1453-60.
291. Vercueil L, Benazzouz A, Deransart C, Bressand K, Marescaux C, Depaulis A, et al. High-frequency stimulation of the subthalamic nucleus suppresses absence seizures in the rat: Comparison with neurotoxic lesions. Epilepsy Res 1998; 31: 39-46.
292. Benabid AL, Koudsie A, Benazzouz A, Vercueil L, Fraix V, Chabardes S, et al. Deep brain stimulation of the corpus luysi (subthalamic nucleus) and other targets in Parkinson's disease. Extension to new indications such as dystonia and epilepsy. J Neurol 2001; 248 (Suppl 3): S37-47.
293. Neme S, Montgomery E, Lüders HO, Rezai A. Seizure outcome of deep brain stimulation of the subthalamic nucleus for intractable focal epilepsy. Epilepsia 2001; 42 (Suppl 2): S124.
294. Velasco F, Velasco M, Velasco AL, Jiménez F, Márquez I, Rise M. Electrical stimulation of the centromedian thalamic nucleus in control of seizures: Long-term studies. Epilepsia 1995; 36: 63-71.
295. Velasco F, Velasco M, Jiménez F, Velasco AL, Brito F, Rise M, et al. Predictors in the treatment of difficult-to-control seizures by electrical stimulation of the centromedian thalamic nucleus. Neurosurgery 2000; 47: 295-304.
296. Weiss SR, Li XL, Rosen JB, Li H, Heynen T, Post RM, Quenching: Inhibition of development and expression of amygdala kindled seizures with low frequency stimulation. Neuroreport 1995; 6: 2171-6.
297. Velasco AL, Velasco M, Velasco F, Menes D, Gordon F, Rocha L, et al. Subacute and chronic electrical stimulation of the hippocampus on intractable temporal lobe seizures: Preliminary report. Arch Med Res 2000; 31: 316-28.
298. Velasco M, Velasco F, Velasco AL. Centromedian-thalamic and hippocampal electrical stimulation for the control of intractable epileptic seizures. J Clin Neurophysiol 2001; 18: 495-513.
299. Loddenkemper T, Pan A, Neme S, Baker KB, Rezai AR, Dinner DS, et al. Deep brain stimulation in epilepsy. J Clin Neurophysiol 2001; 18: 514-32.